Citation Number
1
Views
8
Downloands
3
Giriş: Aterosklerotik kalp hastalıkları tüm dünyada önde gelen morbidite ve mortalite nedenidir. Aterosklerozun patogenezine bakıldığında, dislipidemiler en yaygın ve düzeltilebilen risk faktörlerinden biridir. Bu çalışmamızda kardiyoloji kliniğinde takip etmekte olduğumuz koroner arter hastalığı nedeniyle lipid düşürücü tedavi alması gereken hastaların lipid düşürücü ilaç tedavileri ve lipid düzeylerinin incelenmesi amaçlanmıştır. Yöntem: Aralık 2018 ile Temmuz 2019 arasında kardiyoloji kliniğine başvuran daha önce koroner anjiografi ile koroner arter hastalığı dökümante edilmiş hastalar lipid düşürücü ilaç tedavileri yönünden incelendi. Bulgular: Lipid düşürücü ilaç kullanan grupta total kolesterol ve LDL-kolesterol seviyelerinin anlamlı olarak düşük olduğu tespit edildi (sırasıyla 198.1±40.4 ve 171.6±35.1, p≤0.001, 118,69±36.4 ve 92.2±31.5, p≤0.001). LDL-kolesterol<55 mg/dL hedef değerine ulaşan hastaları incelediğimizde, lipid düşürücü ilaç kullanmayan grupta bir hastada hedefe ulaşılırken, lipid düşürücü tedavi alan grupta 20 hastanın hedefe ulaştığı gözlendi (p=0.023). Sonuç: Çalışmamızda koroner arter hastalığı nedeniyle çok yüksek risk grubunda olan ve ikincil koruma amaçlı lipid düşürücü tedavi alması gereken hastaların etkin dozda ilaç kullanmadıkları tespit edildi. Lipid düşürücü tedavi alan hastalarda kullanılan dozdan bağımsız olarak LDL-kolesterol hedefine ulaşan hasta sayısı düşük bulunmuştur.
Aterosclerotic heart disease is the world’s leading cause of morbidity and mortality. With regard to the pathogenesis of aterosclerosis, dislipidemia is one of the common and corrected risk factors. This study aims to study the lipid-reducing medication treatments and lipid levels of patients who need lipid-reducing treatment due to the coronary artery disease we are monitoring in the cardiological clinic. Method: Patients previously registered with coronary angiography and coronary arterial disease who apply to the cardiology clinic between December 2018 and July 2019 were examined in the direction of lipid-reducing medication treatments. Results: The total cholesterol and LDL cholesterol levels were significantly low in the group that used lipid-reducing drugs (respectively 198.1±40). 4 and 171.6±35.1, p≤0.001, 118.69±36.4 and 92.2±31.5, p≤0.001. When we studied patients with LDL cholesterol <55 mg/dL target, a patient in the group that did not take lipid-reducing drugs was targeted, while 20 patients in the group that received lipid-reducing treatment were targeted (p=0.023). The result: Our study found that patients with a very high risk group due to coronary artery disease and who need secondary protection lipid-reducing treatment did not take the drug in an effective dose. The number of patients who have reached the LDL cholesterol target, regardless of the dose used, was found low in patients receiving lipid-reducing treatment.
Introduction: Atherosclerotic heart disease is the leading cause of morbidity and mortality worldwide.When we look at the pathogenesis of atherosclerosis, dyslipidemias are one of the most common and correctable risk factor. In this study, we aimed to investigate lipid-lowering drug therapies and lipid levels in patients who needed lipid-lowering therapy due to coronary artery disease in cardiology clinic. Method: Patients who were previously documented with coronary artery disease by coronary angiography between December 2018 and July 2019 were examined for lipid-lowering therapy. Result: Total cholesterol and LDL-cholesterol levels were significantly lower in the lipid lowering group (198.1±40.4 ve 171.6±35.1, p≤0.001, 118,69±36.4 ve 92.2±31.5, p≤0.001, respectively). When we analyzed patients reaching LDL-cholesterol<55 mg / dL target value, one patient in the non-lipid lowering group achieved the target, while 20 patients in the lipid lowering group achieved the target (p=0.023). Conclusion: In our study, it was found that the patients who were in a very high risk group due to coronary artery disease and who needed lipid-lowering treatment for secondary prevention did not use effective doses of medication.[o1] The number of patients achieving LDL-cholesterol target was low in patients receiving lipid lowering therapy regardless of the dose used.
Field : Sağlık Bilimleri
Journal Type : Ulusal
Article Detail 
Citation Owners
Similar Articles
Download PDF
Journal Information
Listen Paper
Print This Page
Share
Mendeley
